Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

NCT02009423 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Gastro-Intestinal Stromal Tumour

Interventions

DRUG: Masitinib
DRUG: Placebo

Sponsor

AB Science